Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 15c; Offers FY23 Revenue Guidance
May 4, 2023 8:22 AM EDTIntra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.46), $0.15 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $95.3 million versus the consensus estimate of $91.4 million.
GUIDANCE:
Intra-Cellular Therapies sees FY2023 revenue of $430-455 million, versus the consensus of $448... More
